Key Highlights

  • Delcath Systems (NASDAQ:DCTH) surged about 36% on November 9, 2026, closing near USD 14.93, after reporting record third-quarter revenue.
  • Total Revenue rose about 71% to USD 35.1 million from USD 20.6 million, led by HEPZATO KIT sales of USD 32.7 million against USD 19.3 million a year earlier.
  • Net income reached USD 7.0 million, or USD 0.17 per diluted share, and adjusted EBITDA more than doubled to USD 11.5 million.
  • The company raised 2026 revenue guidance to USD 115 million to USD 117 million, implying HEPZATO KIT Volume growth of at least 41% over 2025.

What Drove the Quarter

Delcath Systems (NASDAQ:DCTH) sells HEPZATO KIT, a system that delivers high-dose chemotherapy directly to the liver while filtering the drug from the blood before it returns to the rest of the body. It is approved in the United States for patients with uveal melanoma that has spread to the liver, and the related CHEMOSAT device is sold in Europe. Third-quarter HEPZATO KIT revenue rose to USD 32.7 million, with treatment volumes up about 72% from a year earlier, while CHEMOSAT revenue rose to USD 2.4 million from USD 1.3 million. Gross Margin improved to 89% from 87%, among the highest in medical devices. The company now has 33 active treatment centres and aims for at least 36 by the end of 2026. Each new centre adds capacity, and volumes tend to build as surgical teams gain experience with the procedure.

Profitability and Balance Sheet

The quarter showed operating leverage. Net Income rose to USD 7.0 million from USD 0.8 million, and adjusted EBITDA more than doubled to USD 11.5 million from USD 5.3 million, even as Research and Development spending rose to USD 11.0 million and selling, general and administrative costs increased to USD 13.1 million to support expansion. Operating Cash Flow was USD 8.2 million. Cash and short-term investments totalled USD 104.3 million at September 30, 2026, and the company has no debt, which allows it to fund new Clinical Trials without immediate reliance on capital markets. Full-year guidance now calls for revenue of USD 115 million to USD 117 million, gross margin of 87% to 89% and positive adjusted EBITDA. For a small-cap medical technology company, this combination of growth and profit is relatively rare and supports a premium valuation.

Pipeline and Risks

The longer-term opportunity for Delcath Systems (NASDAQ:DCTH) lies in expanding beyond uveal melanoma. A Phase 2 trial called DELUMA is testing HEPZATO with standard care in breast cancer that has spread to the liver, with the first patient dosed in July 2026 and about 90 patients planned across more than 20 sites. The company plans to file an investigational application in cholangiocarcinoma, a bile duct cancer, in early 2027. Risks include dependence on a single approved indication, the complexity of the procedure, which limits how quickly centres can be added, competition from new systemic therapies and the possibility that expansion trials fail. Investors will watch centre additions, quarterly treatment volumes and enrolment progress in the DELUMA trial. The sharp rise also lifts expectations, so any slowdown in volume growth could weigh on the shares after such a strong move.

Where Things Stand

Delcath surged about 36% on November 9, 2026 after third-quarter revenue rose about 71% to USD 35.1 million, net income reached USD 7.0 million and full-year guidance was raised to USD 115 million to USD 117 million. A debt-free Balance Sheet with USD 104.3 million of cash funds expansion trials. Centre growth, treatment volumes and progress in breast cancer and bile duct cancer are the next tests.